Liquid Biopsies: Genotyping Circulating Tumor DNA

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2014 Jan 23

PMID 24449238

Citations 1068

Authors

Luis A Diaz Jr

Alberto Bardelli

Affiliations

Soon will be listed here.

Abstract

Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these sequence alterations are highly informative, sampling tumor tissue has significant inherent limitations; tumor tissue is a single snapshot in time, is subject to selection bias resulting from tumor heterogeneity, and can be difficult to obtain. Cell-free fragments of DNA are shed into the bloodstream by cells undergoing apoptosis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and prognosis. Moreover, recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of cfDNA for somatic genomic alterations found in tumors. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.

Citing Articles

Cell-free DNA for detection and monitoring of extramedullary AML relapse.

Hupe H, Wienecke C, Bartels S, Schipper E, Lessmann J, Lasch A Hemasphere. 2025; 9(3):e70097.

PMID: 40066001 PMC: 11891922. DOI: 10.1002/hem3.70097.

DAGIP: alleviating cell-free DNA sequencing biases with optimal transport.

Passemiers A, Tuveri S, Jatsenko T, Vanderstichele A, Busschaert P, Coosemans A Genome Biol. 2025; 26(1):49.

PMID: 40055826 PMC: 11887355. DOI: 10.1186/s13059-025-03511-y.

Development of a prediction model for ctDNA detection (Cir-Predict) in breast cancer.

Nakauchi C, Masunaga N, Kagara N, Oshiro C, Shimoda M, Shimazu K Breast Cancer Res Treat. 2025; .

PMID: 40055250 DOI: 10.1007/s10549-025-07647-0.

Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine.

Bamodu O, Chung C, Pisanic 2nd T J Liq Biopsy. 2025; 2:100126.

PMID: 40028482 PMC: 11863985. DOI: 10.1016/j.jlb.2023.100126.

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.

Parisi C, Tagliamento M, Belcaid L, Aldea M, Bayle A, Remon-Masip J J Liq Biopsy. 2025; 1:100007.

PMID: 40027283 PMC: 11863815. DOI: 10.1016/j.jlb.2023.100007.

References

He Y, Wu J, Dressman D, Iacobuzio-Donahue C, Markowitz S, Velculescu V . Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature. 2010; 464(7288):610-4. PMC: 3176451. DOI: 10.1038/nature08802. View

Newton C, Graham A, Heptinstall L, Powell S, Summers C, Kalsheker N . Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989; 17(7):2503-16. PMC: 317639. DOI: 10.1093/nar/17.7.2503. View

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

Park J, Kim H, Choi B, Lee H, Jang H, Song K . Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett. 2012; 3(4):921-926. PMC: 3362424. DOI: 10.3892/ol.2012.592. View

Azad N, Zahnow C, Rudin C, Baylin S . The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013; 10(5):256-66. PMC: 3730253. DOI: 10.1038/nrclinonc.2013.42. View

Overman M, Modak J, Kopetz S, Murthy R, Yao J, Hicks M . Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol. 2012; 31(1):17-22. PMC: 5545102. DOI: 10.1200/JCO.2012.43.1718. View

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

Liu Q, Sommer S . Pyrophosphorolysis-activated polymerization (PAP): application to allele-specific amplification. Biotechniques. 2000; 29(5):1072-6, 1078, 1080 passim. DOI: 10.2144/00295rr03. View

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

10.

Papageorgiou E, Karagrigoriou A, Tsaliki E, Velissariou V, Carter N, Patsalis P . Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med. 2011; 17(4):510-3. PMC: 3977039. DOI: 10.1038/nm.2312. View

11.

Li M, Diehl F, Dressman D, Vogelstein B, Kinzler K . BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006; 3(2):95-7. DOI: 10.1038/nmeth850. View

12.

Goncalves R, Bose R . Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw. 2013; 11(2):174-82. DOI: 10.6004/jnccn.2013.0025. View

13.

Punnoose E, Atwal S, Liu W, Raja R, Fine B, Hughes B . Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012; 18(8):2391-401. DOI: 10.1158/1078-0432.CCR-11-3148. View

14.

Delgado P, Alves B, Gehrke F, Kuniyoshi R, Wroclavski M, Del Giglio A . Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol. 2012; 34(2):983-6. DOI: 10.1007/s13277-012-0634-6. View

15.

Salvianti F, Pinzani P, Verderio P, Ciniselli C, Massi D, De Giorgi V . Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One. 2012; 7(11):e49843. PMC: 3507877. DOI: 10.1371/journal.pone.0049843. View

16.

Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

17.

Murtaza M, Dawson S, Tsui D, Gale D, Forshew T, Piskorz A . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-12. DOI: 10.1038/nature12065. View

18.

Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F . Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007; 120(11):2439-44. DOI: 10.1002/ijc.22598. View

19.

Diaz Jr L, Williams R, Wu J, Kinde I, Hecht J, Berlin J . The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-40. PMC: 3436069. DOI: 10.1038/nature11219. View

20.

McBride D, Orpana A, Sotiriou C, Joensuu H, Stephens P, Mudie L . Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer. 2010; 49(11):1062-9. PMC: 3145117. DOI: 10.1002/gcc.20815. View